Contact Information: Contacts: David Sheon 202 518-6321 Chris Naughton 011 61 2 9878 0088
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
Worldwide Pivotal Phase III Study in Women With Recurrent Ovarian Cancer Underway in USA, Europe and Australia
| Source: Marshall Edwards Inc.
SYDNEY, AUSTRALIA and BERLIN and NEW CANAAN, CT--(Marketwire - October 23, 2007) - A symposium
on platinum resistant ovarian cancer will be held at the European Society
for Gynecological Oncology in Berlin on Sunday, 28 October. Leading cancer
researchers will speak at the symposium which will focus on advances in
platinum therapies and the potential for phenoxodiol as a promising new
investigational drug to restore platinum sensitivity in platinum resistant
ovarian cancer. Medical professionals interested in listening to the
symposium via the Internet can register for free at
http://www.ovaturetrial/ESGOsymposium.com.
Phenoxodiol is being developed by the US oncology company Marshall Edwards,
Inc. (NASDAQ : MSHL ) as a novel therapeutic in combination with carboplatin
for late-stage chemoresistant ovarian cancers, as well as a monotherapy for
prostate and cervical cancers. Phenoxodiol is a
novel-acting drug that inhibits key pro-survival signaling pathways
operating within cancer cells causing selective cancer cell death and
increased susceptibility to drugs like platinum and taxane, to which most
ovarian cancer patients become resistant in late stage disease.
The Berlin symposium will be chaired by Professor Hani Gabra of the Ovarian
Cancer Action Research Centre, Imperial College London, UK, and Professor
Ignace Vergote, of the Catholic University of Leuven, Belgium.
A major multinational study, the OVArian TUmor REponse (OVATURE) Trial, is
now underway in over 60 centers around the world. This is a major
multi-center multinational Phase III clinical trial of phenoxodiol in women
with advanced ovarian cancer resistant or refractory to
platinum-based drugs, to determine its safety and effectiveness when used
in combination with carboplatin. Preliminary results from the trial are
expected within 18 months. For more information on the trial, visit
www.OVATUREtrial.com.